In a post by Paolo Tarantino on Twitter, it says, “Merck announces positive results for KEYNOTE-756: the addition of pembrolizumab to neoadjuvant chemo significantly improved pCR rate among patients with high-risk HR+/HER2- breast cancer. Follow up ongoing for EFS (co-primary endpoint).”
For the article: Click here
Source:Paolo Tarantino / Twitter